SCHEMBL62823

SCHEMBL62823

CCOC(=O)N1CCCC1C(=O)NC12CCC(CC1)Cn1c2nc(C(=O)NCc2ccc(F)cc2)c(O)c1=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.46
CYP2C9 P11712 2/20 0.44
ALDH1A1 P00352 2/20 0.41
LMNA P02545 3/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
MAPK1 P28482 1/20 0.38
KCNE1 P15382 1/20 0.37
CCR1 P32246 1/20 0.37
KCNQ1 P51787 1/20 0.37
CYP3A4 P08684 1/20 0.36
PKM P14618 1/20 0.36
CYP2C19 P33261 1/20 0.36
HTT P42858 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
NPC1 O15118 1/20 0.34
MAPT P10636 1/20 0.34
CALCA P06881 1/20 0.34
LIPG Q9Y5X9 1/20 0.34
TSHR P16473 1/20 0.34
KDM4E B2RXH2 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL62824 0.95 KCNH2 (0.44) KCNH2CYP2C9ALDH1A1LMNAL3MBTL1
SCHEMBL64070 0.94 KCNH2 (0.47) KCNH2CYP2C9ALDH1A1KCNE1CCR1
SCHEMBL63631 0.92 KCNH2 (0.45) KCNH2CYP2C9ALDH1A1KCNE1CCR1
SCHEMBL63762 0.92 KCNH2 (0.48) KCNH2CYP2C9ALDH1A1KCNE1CCR1
SCHEMBL62603 0.92 KCNH2 (0.48) KCNH2CYP2C9ALDH1A1KCNE1CCR1
SCHEMBL62825 0.90 KCNH2 (0.47) KCNH2CYP2C9ALDH1A1KCNE1CCR1
SCHEMBL63630 0.90 KCNH2 (0.46) KCNH2CYP2C9ALDH1A1KCNE1CCR1
SCHEMBL64080 0.89 KCNH2 (0.46) KCNH2CYP2C9ALDH1A1KCNE1CCR1
SCHEMBL63389 0.89 CYP2C9 (0.49) KCNH2CYP2C9ALDH1A1KCNE1CCR1
SCHEMBL64388 0.89 KCNH2 (0.49) KCNH2CYP2C9ALDH1A1KCNE1CCR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed
WO-2009117540-A1 BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253677-A1 HIV Integrase Inhibitors DNTT, POLB, UNG KCNH2 3969/4885CYP2C9 602/4885ALDH1A1 539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.